MedTrace Logo

Incomplete Response in Late-Life Depression: Getting to Remission With Buprenorphine

NCT02176291 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2018-08-29

Study results available
· View outcomes & findings →

Summary

The purposes of this project are to examine the feasibility, safety, tolerability and clinical effect of low-dose buprenorphine as a novel treatment for late-life treatment-resistant depression and to develop preliminary data about mechanism of action.

Conditions

Interventions

DRUG

Buprenorphine

low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)

DRUG

Placebo

matched placebo

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • Jordan F. Karp

    lead OTHER

Principal Investigators

  • Jordan F. Karp, M.D. · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2017-04-30
Completion
2018-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02176291 on ClinicalTrials.gov